P1184: Phase I Trial of MB-CART2019.1 in Patientes With Relapsed or Refratory B-Cell Non-Hodgkin Lymphoma: 2 Year Follow-Up Report

Borchmann, P.; Lohneis, Anja; Gödel, Philipp; Balke-Want, Hyatt; Schmid, C; Ayuk, Francis A.; Holtkamp, Silke; Hanssens, Linda; Zadoyan, Gregor; Friedrichs, Birte; Assenmacher, Mario; Bürger, Iris; Schneider, Dina; Overstijns, Toon; Scheid, C.; Miltenyi, Stefan; Hallek, Michael

doi:10.1097/01.hs9.0000847600.12970.7d

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The DALY I trial was a phase 1 clinical trial of zamto-cel in patients with R/R B-NHL ( 54 ). Twelve patients were enrolled and six received the recommended dose of 2.5 million cells/kg.…”

Section: B-cell Non-hodgkin Lymphomamentioning

confidence: 99%

Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma

Pang,

Ghosh

2024

Front. Oncol.

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 in B-cell non-Hodgkin lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies. Despite the success, treatment failure due to CD19 antigen loss, mutation, or down-regulation remains the main obstacle to cure. On-target, off-tumor effect of CD19-CAR T leads to side effects such as prolonged B-cell aplasia, limiting the application of therapy in indolent diseases such as chronic lymphocytic leukemia (CLL). Alternative CAR targets and multi-specific CAR are potential solutions to improving cellular therapy outcomes in B-NHL. For Hodgkin lymphoma and T-cell lymphoma, several cell surface antigens have been studied as CAR targets, some of which already showed promising results in clinical trials. Some antigens are expressed by different lymphomas and could be used for designing tumor-agnostic CAR. Here, we reviewed the antigens that have been studied for novel CAR-based therapies, as well as CARs designed to target two or more antigens in the treatment of lymphoma.

show abstract

“…The DALY I trial was a phase 1 clinical trial of zamto-cel in patients with R/R B-NHL ( 54 ). Twelve patients were enrolled and six received the recommended dose of 2.5 million cells/kg.…”

Section: B-cell Non-hodgkin Lymphomamentioning

confidence: 99%

Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma

Pang,

Ghosh

2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…At the EHA2022 Congress, Borchmann presented the 2-year follow-up data from the Phase I/ II trial of zamtocabtagene autoleucel, DALY 1 (NCT03870945). 7,8 DALY 1 is a first-in-human Phase I/II study conducted to evaluate feasibility, dosage, safety, and toxicity of zamtocabtagene autoleucel-expanded autologous T cells that are genetically modified to express an anti-CD20 and CD19 immunoreceptor. The study population consisted primarily of older patients with relapsed/refractory (R/R) CD20-and CD19positive aggressive B cell non-Hodgkin lymphoma.…”

Section: Peter Borchmannmentioning

confidence: 99%

Zamtocabtagene Autoleucel (MB-CART2019.1): An Investigational CAR-T Cell Product with Tandem Targeting of CD19 and CD20 as a Potential Treatment Option for Patients with Relapsed/ Refractory B Cell Non-Hodgkin Lymphoma

Taylor¹

2022

EMJ Hematol

View full text Add to dashboard Cite

Presenting at the European Hematology Association (EHA) 2022 Congress, Peter Borchmann from the University of Cologne, Germany, discussed a novel tandem cluster of differentiation (CD) 19 and CD20 chimeric antigen receptor (CAR)-T therapy for the treatment of patients with relapsed or refractory B cell non-Hodgkin lymphoma. Borchmann presented the 2-year follow up data from DALY 1 trial, which showed that beyond a favourable safety profile, zamtocabtagene autoleucel (MB-CART2019.1) led to durable complete remissions.

show abstract

P1184: Phase I Trial of MB-CART2019.1 in Patientes With Relapsed or Refratory B-Cell Non-Hodgkin Lymphoma: 2 Year Follow-Up Report

Cited by 2 publications

References 0 publications

Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma

Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma

Zamtocabtagene Autoleucel (MB-CART2019.1): An Investigational CAR-T Cell Product with Tandem Targeting of CD19 and CD20 as a Potential Treatment Option for Patients with Relapsed/ Refractory B Cell Non-Hodgkin Lymphoma

Contact Info

Product

Resources

About